S&P/ASX All Ords Index (ASX: XAO) shares are 0.3% lower at 9,240.3 points on Tuesday.
With earnings season now over, brokers have updated their ratings and 12-month price targets on hundreds of ASX shares.
Top broker Morgans reckon these three ASX shares are going to rip over the next year.
Here's why.
Image source: Getty Images
Airtasker Ltd (ASX: ART)
The Airtasker share price is 22 cents, down 2.3% today and down 46% over 12 months.
Morgans kept its buy call on this ASX communications share after reviewing Airtasker's FY26 report.
The broker has a 12-month price target of 47 cents, suggesting a potential near-120% upside ahead.
Morgans said:
Airtasker's (ART) FY26 result was broadly in line with our expectations.
Group revenue grew ~10% on pcp to A$57.8m (marketplaces revenue ex-OneFlare +15.5% to A$52m), and its earlier stage offshore marketplaces (UK/US) showed accelerating momentum and strong topline growth (+55%/150% respectively).
ART also announced media deals with OML and Nova, extending the brand investment runway (media inventory to deploy from FY27 now ~A$24m).
betr Entertainment Ltd (ASX: BBT)
The betr Entertainment share price is steady at 20 cents on Tuesday, and down 33% over 12 months.
Morgans reiterated its buy rating on this ASX retail share after the company's FY26 results.
The broker has a target price of 36 cents, implying a potential 80% upside over the next year.
Morgans said:
BETR Entertainment (BBT) finished the year strongly, with normalised EBITDA of $6.1m in the second half against guidance of $5m to $8m, a $19.3m swing on the first half.
Full year normalised EBITDA of -$7.1m was a touch below our -$6.2m, with a gross profit beat offset by a higher cost of doing business.
Encouragingly, current trading remains healthy. Through the first eight weeks of FY27, turnover is up more than 20%, new customers have almost doubled, CPA is down 31% and promotional cost is down 9%, all excluding the FIFA World Cup.
The company announced the launch of its new first to market 'Wildcards' same game multi (SGM) feature that will launch during the Wildcard AFL round this weekend.
Mach7 Technologies Ltd (ASX: M7T)
The Mach7 Technologies share price is steady at 28 cents today, and down 10% over 12 months.
Morgans reaffirmed its buy rating on the ASX healthcare share after reviewing Mach7's FY26 report.
The broker raised its 12-month price target from 44 cents to 48 cents.
This suggests a potential 70% upside ahead.
Morgans said:
The market should be broadly comfortable with the result given recent trading updates, but new contract delivery remains the key requirement before investors are likely to begin marking the stock materially higher.
Revenue and OPEX landed broadly in line with guidance, while the NPAT miss was driven by a A$1.9m restructuring charge and a weaker tax benefit rather than deterioration in the core subscription business.
Moderate increase in target price due to model roll-forward, lower share count, and leaner-than-expected cost base.
Upside potential to target presents an opportunity but needs new contract momentum to spark renewed interest.
